This article is more than 5 years old. Information may no longer be current.

QLT completes enrollment in AMD combination therapy trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia — QLT has completed enrollment for its phase 2 study to determine if a verteporfin combination therapy reduces re-treatment rates compared with an anti-VEGF antibody while maintaining similar visual acuity and safety among patients with age-related macular degeneration.

The multicenter, randomized, single-masked study — called the RADICAL trial — will compare reduced-fluence Visudyne (verteporfin, Novartis/QLT) combined with Lucentis (ranibizumab, Genentech) to ranibizumab monotherapy in 160 patients with choroidal neovascularization due to AMD. In the study, patients will be randomized to receive one of four treatments: reduced-fluence verteporfin followed by ranibizumab, reduced-fluence verteporfin followed by ranibizumab-dexamethasone triple therapy, very low-fluence verteporfin followed by ranibizumab-dexamethasone triple therapy, or ranibizumab monotherapy.

QLT expects follow-up to last 24 months and plans to report interim results later this year, according to the release.